Silani et al., 2011 - Google Patents
The diagnosis of Amyotrophic lateral sclerosis in 2010Silani et al., 2011
View PDF- Document ID
- 13142740908656651301
- Author
- Silani V
- Messina S
- Poletti B
- Morelli C
- Doretti A
- Ticozzi N
- Maderna L
- Publication year
- Publication venue
- Archives italiennes de biologie
External Links
Snippet
Abstract The diagnosis of Amyotrophic Lateral Sclerosis (ALS) remains in 2010 clinical with neurophysiological support in absence of specific biomarker (s). The disease is diverse in its presentation, cause, and progression. Treatable mimic syndromes must be excluded before …
- 206010002026 Amyotrophic lateral sclerosis 0 title abstract description 164
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Silani et al. | The diagnosis of Amyotrophic lateral sclerosis in 2010 | |
Thome et al. | Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the World Federation of ADHD | |
Fakhoury | Autistic spectrum disorders: A review of clinical features, theories and diagnosis | |
Grudzien et al. | Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease | |
Rapoport et al. | The neurodevelopmental model of schizophrenia: update 2005 | |
Kiernan et al. | Amyotrophic lateral sclerosis | |
Halperin et al. | Serotonin, aggression, and parental psychopathology in children with attention-deficit hyperactivity disorder | |
Monastero et al. | Cognitive impairment in Behçet's disease patients without overt neurological involvement | |
Oades | Role of the serotonin system in ADHD: treatment implications | |
Dekker et al. | Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome | |
WO2017106363A1 (en) | Refining diagnosis and treatment of complex multi-symptom neurological disorders | |
Orsini et al. | Cognitive impairment in neuromuscular diseases: a systematic review | |
Chiò et al. | Comorbidity between CIDP and diabetes mellitus: only a matter of chance? | |
Sel et al. | Nonketotic hyperglycinemia: Clinical range and outcome of a rare neurometabolic disease in a single-center | |
Peterson et al. | Biological basis of childhood neuropsychiatric disorders | |
Jelen et al. | Variants in the zinc transporter-3 encoding gene (SLC30A3) in schizophrenia and bipolar disorder: Effects on brain glutamate–A pilot study | |
Moncrieff | Hemispheric asymmetry in pediatric developmental disorders: Autism, attention-deficit/hyperactivity disorder, and dyslexia | |
Schottlaender et al. | Multiple system atrophy: clinical, genetics, and neuropathology | |
Mazur-Kolecka et al. | Altered development of neuronal progenitor cells after stimulation with autistic blood sera | |
Yuan et al. | Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis | |
Wu et al. | Cognitive impairment, neuroimaging abnormalities, and their correlations in myotonic dystrophy: a comprehensive review | |
Wei et al. | Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline | |
Love et al. | Psychiatric Diseases | |
Patwardhan | Gender-Specific Differences in Cognitive Functions and Alzheimer’s Risk in Type 2 Diabetes Mellitus | |
Blandiaux et al. | PCI & Auditory ERPs for the diagnosis of disorders of consciousness: a EEG-based methods comparison study |